Researchers at Stanford University have developed a novel platform for genetically engineering cells within a living organism, circumventing previous limitations related to accessing target tissues and the size of the genetic payload.
Stanford researchers have developed a new gene editing approach that enables red blood cell-specific gene expression for the treatment of enzyme deficiencies.
Genome editing of human hematopoietic stem and progenitor cells (HSPCs) has the potential to create a new class of medication for the treatment of inherited and acquired genetic diseases of the blood and immune system.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
The cost of DNA and RNA sequencing have decreased in recent years to aid effective research and clinical applications; however, the labor time and throughput of preparing DNA and RNA sequencing libraries remains a challenge.
Inherently, the telomeres located at the ends of chromosomes shorten during each cycle of DNA replication and cell division, eventually topping DNA replication and leading to cell senescence and death.
Stanford researchers have developed a new technology, Variant-FlowFISH, to enable high-throughput, highly sensitive measurements of how variants, introduced via CRISPR, affect gene expression.
Stanford researchers have developed novel technology that combines AAVMYO, a muscle cell targeting viral vector, with CRISPR base editors to achieve targeted gene repair, showcasing over 70% correction of hereditary mutations in cardiomyocytes.
To overcome current gene editing safety, efficacy, and scope limitations, Stanford researchers in the Mackall Lab and Stanley Qi Lab developed MEGA (Multiplexed Effector Guide Arrays), a versatile and multifunctional platform for programmable and scalable regulation of the T c
Stanford researchers have developed a new methodology called transcript-informed single-cell CRISPR sequencing (TISCC-Seq), for the direct detection and phenotyping of genetic variants in a high-throughput manner.
Researchers at Stanford have identified the use of the drug verteporfin to treat or reduce the risk of developing ibrosis after ocular procedures or ocular injury. Of interest is corneal injury, for example after refractive surgery or crosslinking, e.g.
Researchers at Stanford have developed innovative Verteporfin conjugates that considerably enhance the solubility and therapeutic potential of Verteporfin.